📣 VC round data is live. Check it out!
- Public Comps
- Theravance
Theravance Valuation Multiples
Discover Theravance's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Esperion Therapeutics, Odyssey Therapeutics, HK inno.N, Allergy Therapuetics and more.
Theravance Overview
About Theravance
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Founded
2013
HQ

Employees
97
Website
Financials (LTM)
EV
$449M
Valuation Multiples
Start free trialTheravance Financials
Theravance reported last 12-month revenue of $111M.
In the same LTM period, Theravance generated $111M in gross profit and $120M in net income.
Revenue (LTM)
Theravance P&L
In the most recent fiscal year, Theravance reported revenue of $107M and EBITDA of $135M.
Theravance is profitable as of last fiscal year, with EBITDA margin of 125% and net margin of 99%.
Financial data powered by Morningstar, Inc.
Theravance Stock Performance
Theravance has current market cap of $803M, and enterprise value of $449M.
Market Cap Evolution
Theravance's stock price is $15.58.
Theravance share price decreased by 3.0% in the last 30 days, and increased by 41.3% in the last year.
Theravance has an EPS (earnings per share) of $2.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $449M | $803M | -2.3% | -3.0% | -4.0% | 41.3% | $2.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTheravance Valuation Multiples
Theravance trades at 4.0x EV/Revenue multiple, and 3.3x EV/EBITDA.
EV / Revenue (LTM)
Theravance Financial Valuation Multiples
As of June 4, 2026, Theravance has market cap of $803M and EV of $449M.
Theravance has a P/E ratio of 6.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Theravance Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Theravance Margins & Growth Rates
Theravance grew revenue by 9% and net profit by 31% in the last fiscal year.
In the most recent fiscal year, Theravance reported EBITDA margin of 125% and net margin of 99%.
Theravance Margins
Theravance Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Theravance Operational KPIs
Theravance's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Theravance Competitors
Theravance competitors include Esperion Therapeutics, Odyssey Therapeutics, HK inno.N, Allergy Therapuetics, Kura Oncology, Amphastar Pharma, ORIC Pharmaceuticals, Blue Jet Healthcare, Oneness Biotech and Basilea Pharmaceutica.
Most Theravance public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.2x | 2.3x | 14.1x | 13.1x | |||
| 215.2x | 372.3x | (4.5x) | (4.0x) | |||
| 1.4x | 1.4x | 9.7x | 9.3x | |||
| 11.2x | 9.9x | (25.4x) | (20.9x) | |||
| 3.6x | 3.0x | (0.9x) | (0.8x) | |||
| 1.7x | 1.7x | 5.0x | 5.3x | |||
| - | - | (3.6x) | (3.4x) | |||
| 7.9x | 7.6x | 20.7x | 24.2x | |||
This data is available for Pro users. Sign up to see all Theravance competitors and their valuation data. Start Free Trial | ||||||
Investments by Theravance
Theravance has invested in 1 company to date.
Latest investment by Theravance was on June 3rd 2021. Theravance invested in ImaginAb in their $13M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Theravance
| Description | ImaginAb is a Gothenburg-based biotechnology company developing minibodies and diabodies for immunoPET imaging and radiopharmaceutical therapies. Its lead 89Zr-DFO-ABY-025 targets HER2 in breast cancer trials, while CD8 ImmunoPET licenses to Merck and Bristol Myers Squibb for immunotherapy monitoring. Phase II studies enroll patients across US and Europe. Founded in 2010, ImaginAb collaborates with 15 pharma partners worldwide. |
| HQ Country | |
| HQ City | Los Angeles, CA |
| Deal Date | 3 Jun 2021 |
| Round | Series A |
| Raised | $13M |
| Investors | Adage Capital Management; Cycad Group; James Pallotta; Norgine Ventures; Theravance |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Theravance investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Theravance
| When was Theravance founded? | Theravance was founded in 2013. |
| Where is Theravance headquartered? | Theravance is headquartered in United States. |
| How many employees does Theravance have? | As of today, Theravance has over 97 employees. |
| Who is the CEO of Theravance? | Theravance's CEO is Rick E. Winningham. |
| Is Theravance publicly listed? | Yes, Theravance is a public company listed on Nasdaq. |
| What is the stock symbol of Theravance? | Theravance trades under TBPH ticker. |
| When did Theravance go public? | Theravance went public in 2014. |
| Who are competitors of Theravance? | Theravance main competitors include Esperion Therapeutics, Odyssey Therapeutics, HK inno.N, Allergy Therapuetics, Kura Oncology, Amphastar Pharma, ORIC Pharmaceuticals, Blue Jet Healthcare, Oneness Biotech, Basilea Pharmaceutica. |
| What is the current market cap of Theravance? | Theravance's current market cap is $803M. |
| What is the current revenue of Theravance? | Theravance's last 12 months revenue is $111M. |
| What is the current revenue growth of Theravance? | Theravance revenue growth (NTM/LTM) is (3%). |
| What is the current EV/Revenue multiple of Theravance? | Current revenue multiple of Theravance is 4.0x. |
| What is the current net income of Theravance? | Theravance's last 12 months net income is $120M. |
| How many companies Theravance has acquired to date? | Theravance hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Theravance has invested to date? | As of June 2026, Theravance has invested in 1 company. |
| What was the last Theravance investment? | On 3rd June 2021 Theravance invested in ImaginAb, participating in a $13M Series A round, alongside Adage Capital Management, Cycad Group, James Pallotta, and Norgine Ventures. |
| In what companies Theravance invested in? | Theravance invested in ImaginAb. |
See public comps similar to Theravance
Lists including Theravance
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
